Related Experiment Video

Updated: May 9, 2026

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy
12:04

Human Neuroendocrine Tumor Cell Lines as a Three-Dimensional Model for the Study of Human Neuroendocrine Tumor Therapy

Published on: August 14, 2012

Neuroendocrine tumors: treatment updates

Simon Khagi1, Muhammad Wasif Saif

  • 1Tufts Medical Center, Tufts University School of Medicine. Boston, MA 02111, USA. skhagi@tuftsmedicalcenter.org

JOP : Journal of the Pancreas
|July 13, 2013
PubMed

Insights

Advanced gastroenteropancreatic neuroendocrine tumors are challenging to treat. Novel targeted therapies are emerging, showing promise for improved treatment options for neuroendocrine malignancies.

Area of Science:

  • Oncology
  • Gastroenterology
  • Medical Oncology

Background:

  • Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) represent a challenging group of neoplasms with limited systemic treatment options for advanced and metastatic disease.
  • The landscape of GEP-NET treatment has seen advancements, with the 2011 approval of targeted therapies everolimus and sunitinib for pancreatic neuroendocrine tumors.
  • This progress has spurred increased interest in novel therapeutic agents for these malignancies.

Purpose of the Study:

  • To highlight new therapeutic options for neuroendocrine tumors presented at the 2013 American Society of Clinical Oncology (ASCO) conference.
  • To underscore the growing focus on neuroendocrine tumors within the oncology community, as evidenced by dedicated sessions at ASCO.
  • To provide insight into novel agents targeting unique pathways in neuroendocrine malignancies.

Main Methods:

  • Review of abstracts presented at the 2013 ASCO conference, specifically those under the new 'neuroendocrine tumor' title.
  • Focus on abstracts #4030, #4031, #4032, and #4136, which address new therapeutic strategies.
  • Analysis of emerging treatments for advanced and metastatic gastroenteropancreatic neuroendocrine tumors.

Main Results:

  • The 2013 ASCO conference featured four abstracts dedicated to neuroendocrine tumors, indicating heightened research interest.
  • These abstracts presented novel therapeutic options targeting specific pathways in neuroendocrine malignancies.
  • The findings suggest a shift towards more targeted and potentially effective treatments for GEP-NETs.

Conclusions:

  • The development and approval of targeted therapies like everolimus and sunitinib have accelerated research into novel agents for GEP-NETs.
  • The dedicated neuroendocrine tumor session at ASCO 2013 signifies a growing recognition of the need for specialized treatment strategies.
  • Emerging therapeutic options presented at ASCO 2013 offer new hope for patients with advanced and metastatic gastroenteropancreatic neuroendocrine tumors.

More Related Videos

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells10:01

Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells

Published on: August 2, 2022

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...